Mirum Pharmaceuticals, Inc. (MIRM) stock analysis
In our weekly check, Mirum Pharmaceuticals, Inc. is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 9 pass, warnings: 3, red flags: 10.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as MIRM.
What our checks show for MIRM
Red flags
- The company has net debt but no positive operating earnings (EBITDA) to service it from, and equity is negative: on the balance sheet, liabilities exceed assets.
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- The gross margin fell by 8.4 points, to 81.7%: costs are rising faster than prices.
- Weak EPS growth
- The company is losing money: the net margin is -135%.
- Free cash flow is negative (-75% of revenue): the business spends more cash than it brings in.
- The stock has fallen as much as 64% from a peak. Would you have held through that?
- The share count grew by 22.8% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Analysts expect earnings per share to shrink about 60.4% a year.
- The price swings a lot: 49.4% annual volatility. Expect large ups and downs.
Strengths
- The net margin rose by 304 points over 5 years, to -135%.
- Analysts expect revenue to grow about 27.3% a year over the next years.
- Analysts expect the net margin to improve by 149 points from today's -135%.
- Revenue grew 106% a year over the last 3 years.
- After its deepest fall the stock recovered in about 5 months.
- Beta 0.49: the stock usually moves less than the market.
Similar companies
LGND · IBRX · CAI · BLTE · CGON · ARWR
Questions
What grade does Mirum Pharmaceuticals, Inc. (MIRM) have?
In our weekly check, Mirum Pharmaceuticals, Inc. is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 9 pass, warnings: 3, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of MIRM stock?
This week's biggest flags for Mirum Pharmaceuticals, Inc.: High debt, Weak interest cover, Gross margin falling. In total 13 of 22 checks show a warning or a red flag.
What does Mirum Pharmaceuticals, Inc. do?
Mirum Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as MIRM.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis